5 Amendments of Frédérique RIES related to 2010/2153(INI)
Amendment 43 #
Motion for a resolution
Recital E
Recital E
Amendment 68 #
Motion for a resolution
Recital I c (new)
Recital I c (new)
Ic. whereas lawsuits were taken in various Member States, alleging corruption and conspiracy on the part of civil servants in relation to contracts signed in summer 2009 between ministries of public health and manufacturers of A/H1N1 influenza vaccines,
Amendment 106 #
Motion for a resolution
Paragraph 4
Paragraph 4
4. Calls for immediate clarifications onall the relevant lessons swiftly to be learned from the ineffectiveness of the A/H1N1 influenza vaccination strategiesy recommended in the EU, given the weight of evidence casting doubt on their effectiveness, and introduced in the 27 Member States in an uncoordinated manner, given the absence of reliable data guaranteeing thatits effectiveness and the lingering uncertainties surrounding theirits benefit-risk profile;
Amendment 131 #
Motion for a resolution
Paragraph 8
Paragraph 8
8. Considers the conflicts of interest apparent in the case of some experts who advise the European institutions to give rise to suspit normal and not in itself reprehensible that experts who work for public authorities should have links, through other consultancy work, with manufacturers of mediciones of undue influence and to undermine the overall credibility of the European health agencies and their recommendations; calls inr vaccines, but also considers it essential, in order to avoid any risk of conflicts of interest, for the relevant authorities at both national and European level, and particular forly the EMA and ECDC, to revise forthwith their current and future expert screening procedures to ensure complete transparencymake sure that their experts proceed in a fully transparent and independent manner, following all the steps of a clearly identified procedure, from the stage of declaring interests through to the approval of opinions to be issued;
Amendment 148 #
Motion for a resolution
Paragraph 10
Paragraph 10
10. Calls for full liability for the quality, safety and effectiveness of a medicinal product to rest with the manufacturer once it has been established that the product is defective and that compensation is therefore payable;